• 1
    Edgren G, Nyren O, Melbye M. Cancer as a ferrotoxic disease: are we getting hard stainless evidence? J Natl Cancer Inst 2008; 100: 976-977.
  • 2
    Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 2006; 103: 14901-14906.
  • 3
    Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 2007; 6: 1982-1994.
  • 4
    Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. HEPATOLOGY 2001; 33: 647-651.
  • 5
    Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003; 125: 1733-1741.
  • 6
    Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008; 100: 996-1002.
  • 7
    Edgren G, Reilly M, Hjalgrim H, Tran TN, Rostgaard K, Adami J, et al. Donation frequency, iron loss, and risk of cancer among blood donors. J Natl Cancer Inst 2008; 100: 572-579.
  • 8
    Robinson JP, Johnson VL, Rogers PA, Houlston RS, Maher ER, Bishop DT, et al. Evidence for an association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1460-1463.
  • 9
    Syrjakoski K, Fredriksson H, Ikonen T, Kuukasjarvi T, Autio V, Matikainen MP, et al. Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients. Int J Cancer 2006; 118: 518-520.
  • 10
    Shi Z, Johnstone D, Talseth-Palmer BA, Evans TJ, Spigelman AD, Groombridge C, et al. Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age. Int J Cancer 2009; 125: 78-83.
  • 11
    Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-4588.
  • 12
    Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2009; doi:10.3324/haematol.2009.011429.
  • 13
    Osborne NJ, Gurrin LC, Allen KJ, Costantine CC, Delatycki MB, McLaren CE, et al. HFE C282Y homozygotes are at increaed risk of breast and colorectal cancer. HEPATOLOGY 2010; 51: 13111318.
  • 14
    Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221-230.
  • 15
    Gurrin LC, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 2008; 135: 1945-1952.
  • 16
    Santos GC, Zielenska M, Prasad M, Squire JA. Chromosome 6p amplification and cancer progression. J Clin Pathol 2007; 60: 1-7.
  • 17
    Dongiovanni P, Fracanzani A, Cairo G, Megazzini CP, Gatti S, Rametta R, et al. Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol 2010; 176: 1006-1017.
  • 18
    Valenti L, Conte D, Piperno A, Dongiovanni P, Fracanzani AL, Fraquelli M, et al. The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J Med Genet 2004; 41: 946-950.